If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

Hims & Hers’ decision to advertise at the Super Bowl represents an ambitious play for the brand as it positions itself in the ...

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...